J-Brain Cargo, which is a JCR proprietary technology, allows the delivery of biotherapeutics into the central nervous system via a mechanism called receptor-mediated transcytosis.
The first drug approved in Japan using the J-Brain Cargo technology is IZCARGO for the treatment of a lysosomal storage disease with significant central nervous signs and symptoms.
Since the platform technology has broad applicability to many therapeutic effectors, it has the potential to treat multiple CNS indications. The agreement with Alexion is the first international partnership to apply the J-Brain Cargo technology for the treatment of a neurodegenerative disease.
Under the terms of the agreement, the two companies will begin research and development of new treatments using the J-Brain Cargo Technology in combination with an undisclosed effector molecule.
During the research period, Alexion also has the option to nominate additional therapeutic protein candidates in undisclosed indications. Following pre-clinical development, Alexion may exercise its option to further develop and commercialize new drug candidates under this collaboration.
JCR will receive an immediate upfront payment from Alexion and has the right to receive certain research, development and commercial milestones and royalties upon the achievement of certain milestone events, including on post approval net sales.
The impact of this Research Collaboration, Option and License Agreement on the consolidated business results for the fiscal year ending March 31, 2023 has been incorporated into the business forecast for the current fiscal year.
JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company focused on people with rare and genetic diseases.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference